Report: The Autoimmune Inflammatory Bowel Disease Market Outlook to 2012 TOC

2.1 Immunity and Self Preservation
- 2.1.1 Innate immunity
- 2.1.2 Adaptive immunity
2.2 Autoimmune Disease, Antigens and Autoantibodies
- 2.2.1 Antigens
- 2.2.2 Autoantibodies
2.3 Inflammation, Regulation and Central Matrix Destruction
2.4 Adhesion Molecules, Cytokines and Chemokines
- 2.4.1 Adhesion Molecules
- 2.4.2 Cytokines
- 2.4.3 Chemokines
- 2.4.4 Orchestral Role of Cytokines - Primary Focus for Research
2.5 Aetiology of AI Disease
2.6 Spectrum of Autoimmune Disease
- 2.6.1 Organ-Specific AI Disease
- 2.6.2 Non-Organ Specific AI Disease

3.1 World Sales of Leading Anti-inflammatories, 2006
3.2 Anti-inflammatory Drug Sales by Indication
3.3 Immunomodulation is a Fast Growing Treatment Strategy
- 3.3.1 The Anti-inflammatory Cytokines
3.4 AI Diseases with Biggest Impact on the Pharmaceutical Market

4.1 Immunology of the Bowel
4.2 Adaptive Mucosal Immunity
4.3 Innate Mucosal Immunity
- 4.3.1 Extracellular level
- 4.3.2 Epithelial cell
- 4.3.3 Sub-cellular level
4.4 Paneth Cells

5.1 Ulcerative Colitis and Crohn' s Disease
5.2 Aetiology of IBD
- 5.2.1 Environmental Factors
- 5.2.2 Genetic Predisposition
- 5.2.3 Role of the Adaptive Immune System
- 5.2.4 Role of the Innate Immune System
- 5.2.5 Psychoneuroimmunology and Stress
5.3 Signs, Symptoms and Prognosis of IBD
- 5.3.1 Characteristic Signs of IBD
  - 5.3.1.1 Ulcerative Colitis
  - 5.3.1.2 Crohn' s Disease
- 5.3.2 Characteristic Symptoms of IBD
  - 5.3.2.1 Ulcerative Colitis
  - 5.3.2.2 Crohn' s Disease
- 5.3.3 Characteristic Extra-intestinal Manifestations of IBD
- 5.3.4 Prognosis of IBD
5.4 Diagnosis of IBD
- 5.4.1 Differential Diagnosis of CD and UC
- 5.4.2 Differential Diagnosis of IBD and Other Intestinal Diseases
5.5 Biological markers
- 5.5.1 Faecal Calprotectin
- 5.5.2 Lactoferrin
- 5.5.3 ASCA and pANCA
5.6 Treatment Options for IBD
- 5.6.1 General Supportive Therapy
- 5.6.2 Aminosalicylates
- 5.6.3 Leading Aminosalicylates
- 5.6.4 Pentasa
- 5.6.5 Colazal
- 5.6.6 Dipentum
- 5.6.7 Corticosteroids
- 5.6.8 Immunomodulators
- 5.6.9 Antibiotics
- 5.6.10 Biological Immunomodulators
- 5.6.11 TNF- alpha Antagonists
- 5.6.12 Remicade
- 5.6.13 Humira
- 5.6.14 Enbrel

6.1 World Prevalence Rates
- 6.1.1 Environmental factors
- 6.1.2 Gender and Age
6.2 Economic Burden of IBD
6.3 World IBD Anti-Inflammatory Market
- 6.3.1 The US and Canada
- 6.3.2 Europe - Germany, UK, Italy and France
- 6.3.3 Central and South America
- 6.3.4 Conclusions

7.1 The 5-ASAs Intestinal Anti-inflammatories
- 7.1.1 World Leading Brand Aminosalicylates (5-ASAs)
- 7.1.2 World leading Manufacturers- the Key Players
  - 7.1.2.1 Proctor & Gamble
  - 7.1.2.2 Ferring
  - 7.1.2.3 UCB
  - 7.1.2.4 Salix Pharmaceuticals
- 7.1.3 Global Sales of Mesalazine
7.2 Future 5-ASA Market, 2007-2012
7.3 5-ASA Brand Forecasts, 2007-2012
- 7.3.1 Asacol/ Salofalk
- 7.3.2 Pentasa
- 7.3.3 Colazal
- 7.3.4 Azulfidine EN
- 7.3.5 Dipentum
7.4 Anti-TNF- alpha Antagonists in 2006
- 7.4.1 World Leading Brand Anti-TNF- alpha
7.5 Anti-TNF- alpha Biologicals, 2007-2012
- 7.5.1 Remicade
- 7.5.2 Humira

8.1 Main Pipeline Targets in Phase III
- 8.1.1 Anti-TNF- alpha monoclonal antibodies
- 8.1.2 Cytokine inhibitors
- 8.1.3 Selective adhesion molecule antagonists
- 8.1.4 Others
8.2 Market Pipelines for Anti-TNF- alpha Products
- 8.2.1 Adalimumab - Humira from Abbott
- 8.2.2 Certolizumab- Cimzia from UCB
- 8.2.3 Etanercept - Enbrel from Amgen and Wyeth
- 8.2.4 Onercept from Serono Merck
- 8.2.5 CDP 571 from Biogen
- 8.2.6 Thalidomide
- 8.2.7 Mitogen Activated Protein Kinase
8.3 Market Pipeline for Other cytokine Inhibitors
- 8.3.1 ABT-874 - Anti-IL-12 p40 Antibody from Abbott
- 8.3.2 Tocilizumab- (MRA) Anti-IL-6 Antibody from Roche
- 8.3.3 Daclizumab - Anti-IL-2 Receptor Antibody from Roche
- 8.3.4 Basiliximab - Anti-IL-2 Receptor Antibody from Novartis
- 8.3.5 Fontolizumab - Anti -IFN- gamma Antibody from Biopharma
8.4 Adhesion Molecule Inhibitors
- 8.4.1 Natalizumab from Biogen Idec and Elan
- 8.4.2 MLN-02 from Millennium Pharmaceuticals
- 8.4.3 Alicaforsen (ISIS 2302)
8.5 Others
- 8.5.1 Sargramostim (GM-CSF) Leukine from Schering
- 8.5.2 Visilizumab from Nuvion and PDL Biopharma

6.1 Prevalence Rates of IBD worldwide in 2004
6.2 World Intestinal Inflammatory Market by Revenues
6.3 World Intestinal Inflammatory Market by % Share
6.4 Revenues from the North American Intestinal Anti-inflammatory Market in 2005
6.5 Revenues from the European Intestinal Anti-inflammatory Market in 2005
6.6 Revenues from the Intestinal Anti-inflammatory Market in Latin America, 2005
7.1 Sales of Mesalazine Products during the 12 months to Q3, 2006
7.2 Share of the 5-ASA Market for IBD of Different Brands
7.3 Share of the Mesalazine Market for IBD of Different Brands
7.4 Growth of the 5-ASA Market Worldwide, 2007- 2012
7.5 5-ASA Product Revenues Worldwide, 2007-2012
7.6 Annual growth Rates for 5-ASAs Worldwide, 2007- 2012
7.7 Global Sales for Asacol/Salofalk, 2007-2012
7.8 AGR of Asacol and Salofalk, 2007-2012
7.9 Global Sales of Pentasa, 2007-2012
7.10 AGR for Pentasa, 2007-2012
7.11 Global Sales of Colazal, 2007-2012
7.12 AGR for Colazal
7.13 Global Sales of Azulfidine EN, 2007-2012
7.14 AGR of Azulfidine EN, 2007-2012
7.15 Forecast of Revenue from anti-TNF- alpha Products for the Period 2007-2012
7.16 World Revenues for Remicade, 2007- 2012
7.17 AGR for Remicade, 2007- 2012
7.18 World Revenues for Humira, 2007-2012
7.19 AGR for Humira, 2007-2012

The Autoimmune Inflammatory Bowel Disease Market Outlook to 2012